BNDES to Invest up to USD29m in Vinci Impacto e Retorno IV

BNDES has approved an investment of up to BRL150m (approximately USD29m) in Vinci Impacto e Retorno IV. The vehicle, which targets BRL600m (~USD116m), will invest in medium-sized companies operating in the health care, education, retail, IT, and food sectors in Brazil. Read more… Read More

Warburg Leads USD171m Series B for Chinese Drug Developer Haihe Biopharma

Warburg Pincus led a USD171m Series B for China-based cancer drug developer Haihe Biopharma, with participation from CMB International, Legend Capital, CICC Capital, Beijing Langzi Asiana Asset Management, Chaos Investment, Winfast Holding, and Shanghai International Group, and follow-on from Yingke PE, BioTrack Capital, CSPC Pharmaceutical Group, and Liansheng… Read More



(default archive template)